DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK
申请人:PIERRE FABRE MEDICAMENT
公开号:US20170283432A1
公开(公告)日:2017-10-05
The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.
Twenty-one novelN,4-diphenylpyrimidin-2-amine derivatives have been synthesized as PI3Kγ selective inhibitors and compoundC8demonstrated the most potent inhibitory activity against PI3Kγ kinase.
Described herein are benzisoxazole compounds of formula I:
1
or a pharmaceutically acceptable derivative or prodrug thereof, wherein A-B is N—O or O—N; Ar is an optionally substituted C
5-10
aryl group; R
1
is hydrogen or an optionally substituted group selected from C
1-10
aliphatic, C
5-10
aryl, C
6-12
aralkyl, C
3-10
heterocyclyl, or C
4-12
heterocyclylalkyl; and T, n, R
2
and R
3
are as described in the specification. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3 and JAK mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3<i>H</i>)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation
作者:Sarah Diab、Theodosia Teo、Malika Kumarasiri、Peng Li、Mingfeng Yu、Frankie Lam、Sunita K. C. Basnet、Matthew J. Sykes、Hugo Albrecht、Robert Milne、Shudong Wang
DOI:10.1002/cmdc.201300552
日期:2014.5
so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5‐(2‐(phenylamino)pyrimidin‐4‐yl)thiazole‐2(3H)‐onederivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results